PrimeRFP SCOUT · Federal Contract Recompete Brief

75A50325F80009Doxycycline hyclate 100 MG ORAL tablets — Chartwell Rx LLC

Chartwell Rx LLC holds $76.1M across 576 federal awards, concentrated at Department of Health and Human Services (HHS). This PIID sits alongside 1 related award under parent 36F79720D0198. Competition previously drew 2 offers. Set-aside status: SBA. Recompete timing centers on the Jun 22, 2029 PoP end — agencies typically plan 12–18 months ahead.

Aspr/Orm-Sns

Awarding office

Chartwell Rx LLC

Recipient

Jun 22, 2029

PoP end

$98.7M

Obligated

325412

NAICS

6505

PSC

SBA

Set-aside

2 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Chartwell Rx LLC — $90

Contract facts

SBA

Contract number75A50325F80009

Also listed as36F79720D0198-75A50325F80009

AgencyAspr/Orm-Sns

Awarding officeAspr/Orm-Sns

IncumbentChartwell Rx LLC

UEIER5UA9TYBGH4

NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505

Parent IDIQ / IDV36F79720D0198

Place of performanceCONGERS, NY

PoP end (current)Jun 22, 2029

Obligated$98.7M

DOXYCYCLINE HYCLATE 100 MG ORAL TABLETS is a federal SBA award for Aspr/Orm-Sns held by Chartwell Rx LLC. Estimated value $98.7M ($98.7M obligated). Current period of performance ends Jun 22, 2029. Last award drew 2 bidders. Place of performance: CONGERS, NY.

Recompete timing

Public

● Expiring in 1037 days

Current PoP ends Jun 22, 2029 (1037 days remaining). Agencies typically plan 12–18 months ahead — capture window opens around Dec 22, 2027.

Incumbent footprint

Public record

Chartwell Rx LLC — $76.1M obligated across 576 awards (firm-wide, all agencies) · lead buyer Department of Health and Human Services (HHS).

% of firm-wide obligated ($76.1M) · all agencies

Department of Health and Human Services (HHS)$74.1M · 97%Department of Defense (DOD)$1.9M · 2%

Open full company profile →

Related awards

Same parent · incumbent

SPE2D026F0099

8511936905!OTHER MEDICAL

$649K

Apr 19, 2027

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 75A50325F80009?

75A50325F80009 (Doxycycline hyclate 100 MG ORAL tablets) is a Aspr/Orm-Sns award with an estimated value of $98.7M, currently held by Chartwell Rx LLC. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded 75A50325F80009?

Aspr/Orm-Sns awarded 75A50325F80009 to Chartwell Rx LLC.

Who is the incumbent on 75A50325F80009?

Chartwell Rx LLC is the incumbent with $76.1M across 576 related awards in SCOUT’s public footprint. The current period of performance ends Jun 22, 2029.

When does Chartwell Rx LLC’s 75A50325F80009 come up for recompete?

SCOUT tracks a period-of-performance end of Jun 22, 2029. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Aug 20, 2026 · refreshed monthlyLatest procurement action Dec 22, 2025